- Global Pharma News & Resources

LivaNova Partners with Greg Grunberg to Raise Epilepsy Awareness

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has joined forces with actor and epilepsy advocate Greg Grunberg. The partnership kicked off at the Epilepsy Awareness Day at Disneyland Education Expo, where Grunberg joined LivaNova to raise awareness of seizures, drug-resistant epilepsy (DRE) and the available treatment options.

This press release features multimedia. View the full release here:

Greg Grunberg speaks during Epilepsy Awareness Day at Disneyland (Photo: Business Wire)

Grunberg’s inspiration to speak out about epilepsy comes from his 22-year-old son, Jake, who has epilepsy that is now under control. Finding relief from seizures wasn’t always easy for Jake, who was first diagnosed at age 7. Jake has DRE, which affects one in three people with seizures, and medication alone did not provide adequate seizure control. Jake’s seizures progressively became worse as he grew older. By age 12, he was having hundreds of seizures per day.

Today, Jake is a thriving young adult. His seizures are controlled thanks to his medication, Vagus Nerve Stimulation Therapy® (VNS Therapy), brain surgery, and a combination of lifestyle modifications and treatments. VNS Therapy—a medical device designed to prevent seizures before they start and stop them if they do—has been a constant Jake has relied on for more than 10 years.

“The most important piece of advice I can share with other caregivers and people living with epilepsy is: do not settle. If medication alone isn’t working, know there are other treatments available that are worth exploring,” said Grunberg. “Keep fighting. Keep looking for a better and more effective way of controlling seizures.”

Since Jake’s diagnosis more than 15 years ago, Grunberg has become one of the most prominent and active advocates within the epilepsy community. He has partnered with the Epilepsy Foundation to dispel the stigma and lingering myths about epilepsy, and to encourage people to speak more openly about the condition.

“With his first-hand experience as a parent of someone living with seizures and his passion to bring hope to others affected by epilepsy, Greg Grunberg is the perfect partner to help us bring more attention to drug-resistant epilepsy and the potential of VNS Therapy to improve the lives of people affected by DRE,” said Edward Andrle, LivaNova General Manager of Neuromodulation. “LivaNova is excited to kick off our partnership with Greg during Epilepsy Awareness Month.”

An actor, writer, producer and epilepsy advocate, Grunberg has appeared in numerous feature films, including “Star Wars: The Force Awakens,” “Star Trek Beyond” and, most recently, “A Star is Born,” featuring Bradley Cooper and Lady Gaga. On TV, he is best known for his roles in the HBO film “Paterno” and hit series such as “Heroes,” “Alias” and “Felicity.” He also started Band From TV, an all-celebrity cover band that donates the majority of its earnings to charitable causes. As the band’s drummer, Grunberg donates his portion to the Epilepsy Foundation. He lives outside Los Angeles, where he enjoys spending time with his wife Elizabeth and their three sons.

Greg Grunberg is compensated for his time as an advocate for VNS Therapy.

About Drug-Resistant Epilepsy

An estimated 3.4 million Americans are living with epilepsy, which is the fourth most common neurological disorder–behind migraine, stroke and Alzheimer’s disease. While medication is the first line of treatment for seizures, about one-third of all epilepsy patients have drug-resistant epilepsy–or seizures that continue despite trying multiple antiepileptic drugs. After the first two drugs have failed, there is roughly a 5 percent chance that adding more medication will result in seizure freedom. Despite this, most patients will continue to be prescribed additional medications instead of being evaluated for non-drug therapy options.

About VNS Therapy® for Epilepsy

VNS Therapy is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children 4 years of age and older. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. For more information, visit


Epilepsy—The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

Commonly reported side effects are hoarseness, shortness of breath, sore throat and coughing. Side effects typically occur during stimulation and decrease over time.

See safety information at

Manufactured by LivaNova USA. To contact, visit or call 1-888-867-7846.

©2018 LivaNova USA, Inc, a wholly-owned subsidiary of LivaNova PLC. All rights reserved. LivaNova®, SenTiva®, AspireSR® and VNS Therapy® are registered trademarks of LivaNova USA, Inc.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 4,000 employees. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.

For more information, please visit

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova’s control. You should carefully consider the risks and uncertainties that affect LivaNova, including those described in the “Risk Factors” section of LivaNova’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission.

All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.

View source version on

Editor Details

Last Updated: 26-Nov-2018